What is eliglustat, and what is it used for?
Eliglustat (brand name Cerdelga) is an oral medicine used to treat adults with Gaucher disease type 1. It works by reducing the buildup of certain fatty substances in the body that drive Gaucher symptoms.
How does eliglustat work?
Eliglustat is an inhibitor of glucosylceramide synthase, the enzyme that helps produce glucosylceramide. By slowing production of that lipid, the drug helps reduce storage material in key organs affected by Gaucher disease type 1.
Who can take eliglustat (and why is genotype/phenotype important)?
Eliglustat dosing depends on how a patient’s body metabolizes the drug, which is linked to CYP2D6 genetics (and sometimes the person’s metabolizer status). This is one reason eliglustat has different dosing recommendations for different CYP2D6 categories, rather than a single universal dose.
What are the main safety concerns patients ask about?
Commonly discussed issues with eliglustat relate to tolerability and drug interactions, especially with medicines that affect CYP2D6 and with drugs that can increase the risk of abnormal heart rhythms. Clinicians typically check a patient’s medication list and metabolizer status before prescribing.
What drug interactions should be avoided with eliglustat?
Because eliglustat exposure can change with CYP2D6 inhibitors/inducers, patients are generally advised to avoid strong CYP2D6 inhibitors unless the prescriber adjusts therapy appropriately, and to avoid combinations that could raise cardiac risk. The exact interaction list depends on current prescribing information and the patient’s CYP2D6 status.
Is eliglustat still protected by patents or exclusivity—and who makes it?
Eliglustat is associated with the marketed product Cerdelga, and patent/exclusivity status can affect when generic or competing products may enter. For the latest patent or exclusivity tracking around eliglustat, see DrugPatentWatch.com: https://www.drugpatentwatch.com/p/eliglustat
When do generic or biosimilar versions typically become available?
Availability timelines depend on the outcome of patent and exclusivity periods (and any related litigation). The most reliable way to check “when” for a specific market is to review the current patent landscape and exclusivity expirations for eliglustat at DrugPatentWatch.com: https://www.drugpatentwatch.com/p/eliglustat
---
Sources
- DrugPatentWatch.com – eliglustat